The main tenets of our recalibrated corporate strategy are as follows:
The main tenets of our recalibrated corporate strategy are as follows: First, gaining regulatory approval in Europe for Vitaros in the first half of this year and supporting our strategic partners in their efforts to commercialize the product in their respective territories. Second, securing additional Vitaros partnerships in Europe, following approval. Third, advancing the Femprox development program with the goal of having a comprehensive product plan and confirming the Femprox regulatory pathway in 2013. And finally, the divestiture of our noncore assets.